Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific AgonistGlobeNewsWire • 03/25/24
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor ConferencesGlobeNewsWire • 03/06/24
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 02/22/24
Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in JapanGlobeNewsWire • 02/22/24
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business UpdateGlobeNewsWire • 02/22/24
Rhythm Pharmaceuticals, Inc. (RYTM) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 02/15/24
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024GlobeNewsWire • 01/31/24
Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640GlobeNewsWire • 01/04/24
Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional UpdatesGlobeNewsWire • 01/04/24
Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023GlobeNewsWire • 12/13/23
Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D EventGlobeNewsWire • 12/06/23
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/07/23
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business UpdateGlobeNewsWire • 11/07/23
Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)GlobeNewsWire • 11/02/23
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 10/31/23
Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023GlobeNewsWire • 10/25/23
Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023GlobeNewsWire • 10/17/23
Wall Street Analysts Believe Rhythm Pharmaceuticals, Inc. (RYTM) Could Rally 53.81%: Here's is How to TradeZacks Investment Research • 10/12/23
Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society's Annual Meeting at ObesityWeek ®GlobeNewsWire • 10/10/23
Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic ObesityGlobeNewsWire • 09/19/23
Rhythm Pharmaceuticals Announces Update to September Conference ParticipationGlobeNewsWire • 09/08/23